SCHEMBL317441

SCHEMBL317441

[O]c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
TSHR P16473 5/20 0.47
HSD17B10 Q99714 4/20 0.47
CYP3A4 P08684 3/20 0.47
RECQL P46063 2/20 0.47
HPGD P15428 2/20 0.41
AHR P35869 1/20 0.41
TP53 P04637 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 1/20 0.39
AKR1C4 P17516 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
AKR1C1 Q04828 1/20 0.39
ERN1 O75460 1/20 0.39
KDM4E B2RXH2 2/20 0.37
CES1 P23141 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5004053 0.80 RAPGEF4 (0.43) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL10507454 0.73 NMT1 (0.48) ALDH1A1TSHRCYP3A4AHRTDP1
SCHEMBL3747036 0.73 CES2 (0.33) HPGDCA1CA9CES1
SCHEMBL1805217 0.73 TSHR (0.36) ALDH1A1TSHRHSD17B10HPGDMEN1
SCHEMBL22632969 0.73 CYP3A4 (0.58) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL2937097 0.72 TSHR (0.67) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL6378496 0.72 AKR1C4 (0.45) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL1810206 0.72 CA1 (0.47) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL1804696 0.72 CA1 (0.62) CA1CA2CA9TDP1LMNA
SCHEMBL5961682 0.71 ALDH1A1 (0.61) ALDH1A1TSHRHSD17B10CYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897560-B2 Plasma protein affinity tags NOVO NORDISK A/S (DK) 2011-03-01 US claimed
US-20100184641-A1 Novel Plasma Protein Affinity Tags NOVO NORDISK A/S (DK) 2010-07-22 US claimed
US-7547749-B2 Triazine compounds, polymers comprising triazine structural units, and method SABIC INNOVATIVE PLATICS IP B.V. (NL) 2009-06-16 US claimed
US-20080097040-A1 TRIAZINE COMPOUNDS, POLYMERS COMPRISING TRIAZINE STRUCTURAL UNITS, AND METHOD GENERAL ELECTRIC COMPANY (US) 2008-04-24 US claimed
US-20070105750-A1 Novel plasma protein affinity tags NOVO NORDISK A/S (DK) 2007-05-10 US claimed
EP-1667724-A2 ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES NOVO NORDISK A/S (DK) 2006-06-14 EP claimed
US-20050192411-A1 Triazine compounds, polymers comprising triazine structural units, and method GENERAL ELECTRIC CO. 2005-09-01 US claimed
EP-1066269-B1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2005-05-11 EP claimed
WO-2005028516-A2 ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES NOVO NORDISK A/S (DK) 2005-03-31 WO claimed
EP-1423372-A2 TRIAZINE COMPOUNDS, POLYMERS COMPRISING TRIAZINE STRUCTURAL UNITS, AND PROCESSES FOR THE PREPARATION OF THESE POLYMERS GENERAL ELECTRIC COMPANY (US) 2004-06-02 EP claimed
EP-1066269-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-10 EP claimed
US-6150360-A ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE JANSSEN PHARMACEUTICA N.V. (BE) 2000-11-21 US claimed
WO-1999050256-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 1999-10-07 WO claimed
EP-0583806-B1 Acrylic derivatives of 2-thiazolypyrroles having a fungicidal activity MINI RICERCA SCIENT TECNOLOG (IT) 1997-10-15 EP claimed
EP-0554956-B1 Thiazolylpyrroles having a fungicidal activity MINI RICERCA SCIENT TECNOLOG (IT) 1997-10-01 EP claimed
EP-0583806-A1 Acrylic derivatives of 2-thiazolypyrroles having a fungicidal activity MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1994-02-23 EP claimed
US-5241084-A PREPARATION PROCESS OF GINKGOLIDE B FROM GINKGOLIDE C SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1993-08-31 US claimed
EP-0554956-A1 Thiazolylpyrroles having a fungicidal activity MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1993-08-11 EP claimed
US-4579684-A Process for the manufacture of enol derivatives CIBA-GEIGY CORPORATION (US) 1986-04-01 US claimed
US-4293462-A Process for the manufacture of enol derivatives, and intermediates CIBA-GEIGY CORPORATION (US) 1981-10-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184641-A1 Novel Plasma Protein Affinity Tags CD2BP2, HDLBP, SERPINA6 ALDH1A1 4651/4885TSHR 1995/4885HSD17B10 3288/4885
US-20070105750-A1 Novel plasma protein affinity tags CD2BP2, HDLBP, SERPINA6 ALDH1A1 4651/4885TSHR 1995/4885HSD17B10 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.